Injector Product News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RepliCel Launches Testing of Dermal Injector Units ACCESSWIRE Initial units delivered and first phase of functional testing nearly complete VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ('RepliCel' or the 'Company'), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan. 'In ...

RepliCel Life Sciences, Inc.: RepliCel Launches Testing of Dermal Injector Units VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan. "In our February update, we announced that manufacturing of Rep...

RepliCel Launches Testing of Dermal Injector Units Initial units delivered and first phase of functional testing nearly complete VANCOUVER, BC, CANADA - 25 May 2021 - RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ('RepliCel' or the 'Company'), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan. 'In our February updat...

RepliCel Life Sciences, Inc.: RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement MainPointe Deal Positions RepliCel for entry into the U.S. market and significant milestones in Japan VANCOUVER, BC / ACCESSWIRE / January 25, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV: RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has signed three strategic agreements with MainPointe Pharmaceuticals ("MainPointe") headquartered in Louisville, Kentucky (the "...